A Post-market, Observational Registry With the easyEndoTM Universal Linear Cutting Stapler in Laparoscopic Bariatric Surgery
- Conditions
- GastrectomyMini Gastric BypassObesityRoux-en-Y Gastric Bypass
- Interventions
- Device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
- Registration Number
- NCT04422236
- Lead Sponsor
- Duomed
- Brief Summary
The purpose of this observational registry is to evaluate the safety and performance of the easyEndoTM Universal Linear Cutting Stapler and reloads from Ezisurg Medical when used to create anastomoses during laparoscopic bariatric surgery. The goal of the study will be achieved by assessing the device performance and by reporting of peri- and postoperative complications in a prospectively maintained database.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Patient ≥ 18 years of age at registry entry.
- Patient and investigator signed and dated the informed consent form prior to the index-procedure.
- Patient has a BMI ≥ 35 kg/m2, with one or more related co-morbidities.
- Patient has a BMI ≥ 40 kg/m2.
- Patient is eligible for laparoscopic bariatric surgery.
- Patient is unable / unwilling to provide informed consent.
- Patient has a history of bariatric surgery.
- Patient is unable to comply with the registry protocol or proposed follow-up visits.
- Patient has a contra-indication for laparoscopic bariatric surgery.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Obese patients eligible for laparoscopic bariatric surgery easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) -
- Primary Outcome Measures
Name Time Method To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery. Follow-up 6: 24 months after the procedure Number of re-interventions and number of participants with (serious) adverse events ≥ grade II Clavien-Dindo.
- Secondary Outcome Measures
Name Time Method Device performance At index procedure Assessment of device performance (e.g. sharpness of the blade, staple-line formation, etc.).
Clinical efficacy Follow-up 6: 24 months after the procedure Comorbidity
Trial Locations
- Locations (1)
AZ Delta vzw
🇧🇪Roeselare, Belgium